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Abstract
Entry of HIV-1 into target cells requires binding of the viral envelope glycoprotein (Env) to cellular receptors and subsequent
conformational changes that culminates in fusion of viral and target cell membranes. Recent structural information has
revealed that these conformational transitions are regulated by three conserved but potentially flexible layers stacked
between the receptor-binding domain (gp120) and the fusion arm (gp41) of Env. We hypothesized that artificial insertion of
a covalent bond will ‘snap’ Env into a conformation that is less mobile and stably expose conserved sites. Therefore, we
analyzed the interface between these gp120 layers (layers 1, 2 and 3) and identified residues that may form disulfide bonds
when substituted with cysteines. We subsequently probed the structures of the resultant mutant gp120 proteins by
assaying their binding to a variety of ligands using Surface Plasmon Resonance (SPR) assay. We found that a single disulfide
bond strategically inserted between the highly conserved layers 1 and 2 (C65-C115) is able to ‘lock’ gp120 in a CD4 receptor
bound conformation (in the absence of CD4), as indicated by the lower dissociation constant (Kd) for the CD4-induced
(CD4i) epitope binding 17b antibody. When disulfide-stabilized monomeric (gp120) and trimeric (gp140) Envs were used to
immunize rabbits, they were found to elicit a higher proportion of antibodies directed against both CD4i and CD4 binding
site epitopes than the wild-type proteins. These results demonstrate that structure-guided stabilization of inter-layer
interactions within HIV-1 Env can be used to expose conserved epitopes and potentially overcome the sequence diversity of
these molecules.
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Introduction
Approximately 34 million people are infected with Human
Immunodeficiency Virus type 1 (HIV-1) [1]. Although the
epidemic may have stabilized to some extent in many regions
including parts of sub-Saharan Africa [2], where the burden of the
disease has been most severe, a vaccine against HIV-1 remains a
huge unmet medical need globally. Although HIV-1 infected
subjects are able to mount a humoral immune response directed
against the viral envelope glycoprotein (Env) during initial HIV-1
infection, the Env-specific antibodies generated in large part fail to
neutralize the virus nor impact disease progression [3]. This failure
is due to multiple mechanisms of immune evasion inherent to HIV
Env that protect the virus against the host’s antibody responses.
These include a high degree of sequence variability in the viral
Env antigen primarily in its immunodominant ‘‘variable’’ loops,
carbohydrate masking of underlying conserved polypeptide
epitopes, occlusion and conformational masking of key conserved
epitopes and molecular mimicry of self-antigens [4]. Nevertheless,
despite the large degree of Env variability, the virus must maintain
certain conserved sites that bind cellular receptors to mediate cell
entry. These conserved receptor binding sites in HIV-1 gp120,
which include the CD4-binding site (CD4BS) and CD4-induced
(CD4i; co-receptor) binding sites, are potentially vulnerable targets
for antibody-mediated neutralization.
Recent high-resolution gp120 structures [5,6] have revealed the
complete structure of the inner domain of HIV-1 gp120 that was
missing from previous studies [7–10]. These structures showed
that the inner domain of gp120 in CD4-bound state is organized
into 3 layers (layers 1, 2 and 3), projecting from a b-sandwich
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structure towards the target cell membrane (Figure 1) [5,6,11,12].
This domain was identified as the primary region of gp120 that
undergoes extensive conformational changes as it transitions from
the unliganded to CD4-bound state [5,13,14]. Subsequent to CD4
binding, conformational changes in the inner domain contribute
to two essential downstream events required for entry of the virus
into target cells. These include: (i) stabilization of the initial weak
gp120-CD4 contacts, and (ii) exposure of a conserved site on
gp120 for co-receptor binding. In the CD4-bound state of gp120,
the three layers of the inner domain (Figure 1) come together
through specific interlayer interactions and stabilize the CD4-
bound conformation of the viral envelope glycoprotein.
The interactions between layers 1 and 2 are mediated through a
number of residues identified by site-directed mutagenesis [11,12].
Disruption of these inter-layer interactions led to destabilization of
the CD4-bound conformation of gp120 resulting in reduced
affinity to CD4 [11]. Similarly, mutations that reduced interac-
tions between the layers also prevented binding of gp120 to small
molecule CD4-mimetics, such as NBD-556, which require CD4-
bound conformation of the gp120 for a high affinity interaction
[11,15]. Binding of antibodies, such as 17b, 48d and 412d that
recognize the CD4-induced conserved binding sites on gp120 were
also dramatically reduced by mutations that prevented inter-layer
interaction in the inner domain [11]. In general, reduced inter-
layer interactions led to reduced exposure of the conserved
binding sites (i.e. CD4 and CD4-induced/co-receptor binding
sites) and therefore reduced binding of ligands recognizing these
sites.
Previous structure-guided attempts to stabilize gp120 in a
receptor-bound conformation utilized various approaches includ-
ing a combination of disulfide bridges and cavity-filling mutations
[16–18]. The largest degree of stabilization was achieved by the
formation of disulfide bridges after targeted substitution with
cysteine residues [16–18]. While these disulfide-stabilized struc-
tures achieved exposure of the CD4-induced binding sites in
gp120, they also reduced exposure of the CD4-binding sites, as
measured by affinity of CD4 & CD4-binding site antibodies. This
was probably due to direct interference of some of the newly
inserted disulfide bridges with antibody binding. In addition, most
of previously tested disulfide-inserting mutations focused on
stabilizing the inner and outer domain contacts [16–18], rather
than restricting movement within the inner domain. However, as
shown in recent work and described above, the inter-layer
interactions within the inner domain are crucial in determining
the transition of gp120 to CD4-bound conformation [5,6,11,12].
Therefore, unlike previous attempts, we have focused here in
stabilizing the inter-layer contacts within the inner domain by
inserting a disulfide linkage far from the receptor binding area. We
hypothesized that stabilization of the interlayer contacts would put
gp120 into a conformation in which both the CD4 and CD4-
induced binding sites are exposed.
We, therefore, mutated residues at strategically selected sites in
layers 1 and 2 (and layer 3) into cysteines to allow formation of
disulfide bridges that would stabilize the inner domain of gp120.
Analysis of binding affinities of CD4 and anti-gp120 monoclonal
antibodies (mAb) to wild-type gp120 and the final selected
stabilized gp120 (gp120 L1-SS-L2) revealed that the stabilized
protein not only recognized soluble CD4 (sCD4) and CD4BS-
antibodies with similar affinity as wild-type but also recognized
CD4-induced antibody, 17b, with much higher affinity than wild
type and in the absence of sCD4. These stabilized recombinant
Env glycoproteins, both the monomeric gp120 and trimeric
gp140, were shown to elicit robust high titer and high avidity
antibody responses in rabbits, with the stabilized antigens
generating more ‘‘balanced’’ responses directed to multiple
gp120 epitopes with a higher proportion of antibodies directed
against both the CD4i and CD4 binding site epitopes. These
results demonstrate that structure-guided stabilization of inter-
layer interactions within HIV-1 Env can be used to expose
conserved epitopes and potentially overcome the structural
diversity of these molecules when used as vaccine immunogens.
Figure 1. Schematic representation of layered organization of the gp120 inner domain. Ribbon diagram representation showing the
inner domain of gp120 and its organization into three layers: layer 1 (magenta), 2 (green) and 3 (orange). The outer domain of gp120 is shown in
white/gray. The representation is based on RCSB PDB ID - 3JWO [6].
doi:10.1371/journal.pone.0076139.g001
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Results
Structural analysis of proximal residues between layers
allows introduction of appropriate cysteine pairs for
generation of disulfide-stabilized gp120 and gp140
proteins
We examined all residues that lie at the interface of layers 1, 2
and 3, and attempted to identify residues that could be targeted for
substitution with cysteine for disulfide bond formation. In order for
a disulfide bridge to be formed between two cysteine residues, the
side chains have to be at the proper distance and in the right
orientations with respect to each other. We, therefore, used the
distance between C-b (Carbon–beta) atoms as one of the criteria
for selecting residues that would be substituted with cysteines. The
average distances between C-b atoms of cysteines that formed
disulfide bridges in previously determined gp120 structures was in
a range of 3.5Å – 4.7Å [6,17]. In addition, we also examined a
crystal structure of gp120 into which specific amino acids had been
mutated in disulfide bond forming cysteines, W96C-V275C and
I109C-Q428C) [17], and observed that the C-b distances of the
native and cysteine substituted residues, which formed disulfide
bonds, were 4.1Å and 4.3Å, respectively. Therefore, we screened
and selected for residues on interacting layers that had C-b-C-b
distances falling within this (3.5Å – 4.7Å) range.
Based on the C-b distance criteria and expression analysis of a
subset of cysteine mutants that were designed in silico and tested for
expression and antigenicity (binding to CD4 and CD4i-directed
antibody, 17b) post-purification, we identified a pair of residues
that could be substituted with cysteine for disulfide bridging of
layers. Except for one, all mutations in gp120 either failed to
express or could not be purified as homogenous monomeric,
disulfide-stabilized gp120 that was functionally active (i.e., bound
CD4 and underwent CD4-induced conformational change to
allow CD4-directed antibody, 17b, binding) (Table S1). Therefore,
the targets chosen for cysteine substitution to bridge layers 1 and 2
were Valine 65 (from layer 1) and Serine 115 (from layer 2),
(Figure S1A & B). The C-b atomic distance between these residues
in the new CD4 bound gp120 structure is 3.7Å (Figure S1B, [6]),
which was a sufficient distance for disulfide bridging.
These two residues, Valine 65 and Serine 115, were mutated to
cysteine in both gp120 and a cleavage-defective gp140 [19,20]
backbone from HIV-1SF162. Both recombinant disulfide-stabilized
gp120 and cleavage-defective gp140 proteins, along with their
respective wild-type forms, were then expressed via transient
transfection of HEK 293 cells and purified using an established
purification protocol ([19], and Materials and Methods). All four
wild-type and disulfide-stabilized proteins were purified to .95%
purity, as visualized using a coomassie-stained SDS-PAGE
(Figure 2). The disulfide-stabilized gp120 and gp140 are referred
to as gp120 L1-SS-L2 (L1 – layer 1; SS – disulfide linkage; L2 –
layer 2) and gp140 L1-SS-L2, respectively.
To ascertain that disulfide bond was formed in gp120 via the
engineered cysteine residues at position 65 and 115, we used mass
spectrometry. The LC/ESI-FTICR MS data confirmed that
disulfide bond between engineered cysteines at position 65 and
115 was formed and detected in major forms of disulfide-linked
tryptic peptides (Figures S2 and S4).
Insertion of a disulfide linkage increases ligand affinity to
CD4-induced site without affecting CD4 receptor binding
Following structural ‘‘fixation’’ of gp120 and gp140 by the
inserted disulfide bond, we utilized Surface Plasmon Resonance
(SPR) to evaluate the differences in binding affinities between wild-
type and disulfide-stabilized (L1-SS-L2) gp120 proteins to a CCR5
peptide (Figure S3) and soluble CD4, as well as mAbs VRC01,
b12, and 17b (2/+ sCD4) (Figure 3), to determine if the molecules
were indeed ‘locked’ into a CD4 bound state and to what degree
the conserved receptor and co-receptor binding sites were
exposed.
Initial qualitative binding of wild-type and disulfide-stabilized
gp120 proteins, in absence or presence of sCD4, to a 22-mer
tyrosine-sulfated biotinylated N-terminal CCR5 peptide [21]
confirmed the improved exposure of the CD4-induced co-receptor
binding site in the disulfide-stabilized gp120 L1-SS-L2 protein
(Figure S3). Following this, we carried out an in-depth binding
affinity analysis of the two gp120 proteins to CD4, VRC01, b12,
and 17b (2/+ sCD4). When the binding of wild-type and
disulfide-stabilized gp120 proteins to soluble CD4 (sCD4) was
analyzed, we observed that the stabilized gp120 protein bound to
CD4 with .3.5-fold lower affinity than the wild-type gp120
(gp120 wild-type-sCD4: 24.5 nM; gp120 L1-SS-L2-sCD4:
93.1 nM) (Figure 3A & B). This difference in affinity is primarily
attributed to the difference in on-rate (kon) while the off-rates (koff)
are near-identical (Figure 3). Since binding of gp120 to CD4
requires elements of gp120’s inner domain, outer domain and the
bridging sheet, the presence of the disulfide bridge in the inner
domain likely restricted the inherent flexibility of the molecule
thereby affecting the accessibility needed for initial ‘‘docking’’ of
CD4 to gp120, and hence the lower affinity of the stabilized gp120
for CD4 [17]. The affinity between gp120 (wild-type or other
forms) and CD4 (4-domain, 2-domain or CD4-IgG2), measured
previously particularly via non-SPR based methods [22,23],
showed sub-nanomolar affinity. The observed relative difference
in affinity via non-SPR methods could be due to differences in the
strains of the gp120 used, the expression system and level of purity
of the gp120 protein, the buffer systems used and/or their linear
range of quantitation. More importantly, in ELISA the measured
affinity is not based on 1:1 binding and hence can be stronger than
the 1:1-derived affinity from SPR presented here. When binding
to CD4BS-mAb b12 was compared, we observed a similar trend
Figure 2. Expression and purification of disulfide-stabilized
SF162 gp120 and gp140. The two disulfide-stabilized proteins are
referred to as gp120 L1-SS-L2 and gp140 L1-SS-L2. The SS refers to the
disulfide bond. SDS-PAGE followed by coomassie-staining to show
purity of GNA-lectin affinity column and DEAE-column purified (A)
Disulfide stabilized SF162 gp120 L1-SS-L2 (lane 1) and wild-type gp120
(lane 2), and (B) Disulfide stabilized SF162 gp140 L1-SS-L2 (lane 3) and
wild-type gp140 (lane 4). MW refers to Molecular Weight standard/
marker. The gp120 s and gp140 s are indicated by the red arrow.
doi:10.1371/journal.pone.0076139.g002
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but a greater fold-difference. While wild-type gp120 bound with
an affinity of 44.8 nM, the disulfide-stabilized gp120 bound with
,7-fold lower affinity (Kd – 304 nM) (Figure 3C & D). Binding to
more potent CD4BS-mAb VRC01 showed a similar binding trend
in that the disulfide-stabilized gp120 bound VRC01 mAb with
(,2-fold) lower affinity, predominantly attributed to the on-rate
(kon) (Figure 3E & F).
When we compared binding to various mAbs, such as 17b,
which binds to the CD4-induced (CD4i) epitope(s), we found that
while unliganded, wild-type gp120 bound to 17b with an affinity of
301 nM, the unliganded, stabilized gp120 bound with ,700-fold
higher affinity (Kd – 0.44 nM) (Figure 3G & H). Upon ligation
with CD4 (gp120+sCD4), the wild-type gp120 now bound mAb
17b with significantly higher affinity (Kd – 0.26 nM), which was
only ,2-fold better than the affinity with unliganded, stabilized
gp120. The sCD4-liganded, stabilized gp120 (gp120 L1-SS-L2 +
sCD4), on the other hand, bound 17b with ,5-fold higher affinity
(Kd - 0.096 nM) than unliganded, stabilized gp120 (gp120 L1-SS-
L2) (Kd – 0.44 nM) and ,3-fold higher affinity than sCD4-
liganded, wild-type gp120 (gp120+sCD4) (Kd – 0.26 nM)
(Figure 3I & J). Overall, when comparing the affinities to mAb
17b that is dependent on CD4-binding, we observed that the
disulfide stabilization was able to induce a similar level of exposure
to what sCD4 binding induced in a wild-type protein. In addition,
we observed that when sCD4 was pre-incubated to the disulfide-
stabilized gp120 (gp120 L1-SS-L2+sCD4), a further (,5-fold)
increase in affinity (driven predominantly by increased on-rate)
was observed, indicating that the stabilized gp120 was not fully
‘locked’ and/or CD4 can induce a further conformational
alteration and stabilization to enable optimal 17b-binding. These
data confirmed the stabilization of the inter-layer contacts of inner
domain enhanced exposure of CD4-induced epitopes on gp120 in
the absence of the CD4 receptor.
Disulfide-stabilized gp120 and gp140 elicited high titer
and high avidity antibody responses in rabbits
The in vitro binding analysis of the gp120 antigen indicated that
the disulfide-stabilized molecules were likely ‘locked’ into the
intended CD4-bound conformation while preserving exposure of
the CD4 binding site. We, therefore, grafted those mutations onto
the gp140 backbone and generated a similarly disulfide-stabilized
protein, gp140 L1-SS-L2, so that we could evaluate both
monomeric (gp120) and trimeric (gp140) forms of the antigen.
Due to an inability to fit the gp140-sCD4/mAb SPR binding
analysis to the 1:1 Langmuir binding model, we were unable to
report a similar degree of SPR analysis on the stabilized-gp140
protein. Regardless, we wanted to compare the immunogenicity of
the two disulfide-stabilized proteins, gp120 L1-SS-L2 and gp140
L1-SS-L2, to their wild-type counterparts.
Four groups of 5 rabbits each were immunized at 0, 4, and 12
weeks with 25 mg of well-characterized preparations of each Env
proteins using a stable vaccine formulation of the potent Carbopol
971P + MF59 as adjuvant [24]. Env-specific binding antibody
titers and avidities were evaluated in sera following each
immunization. We observed that while the 1st immunization
generated 103256103 geometric mean titers (GMT), the 2nd
protein immunizations improved the titers by #32logs
(561052106); however, after the 2nd immunization, the GMTs
for all groups were comparable and only an incremental
improvement, to a maximal of $106256106 GMTs, was
observed after the 3rd immunization. (Figure 4A). The GMTs
declined at 4wp3, and further at 8wp3 time-points and the rate of
decay was similar in all groups.
When we measured the avidities of the anti-Env antibodies
generated, we observed that after the 1st immunization, all groups
elicited similar levels of low avidity antibodies (Figure 4B). After
the 2nd immunization, in the gp120 groups, there was little or no
increase in avidities; in contrast, the gp140-immunized groups
(both wild-type and disulfide-stabilized) showed a $2-fold
increase. The 3rd immunization resulted in increasing avidities
further, a remarkable $4-fold in the gp120-immunized groups
and 1.5- (gp140) to 2.5- (gp140 L1-SS-L2) fold increased avidity in
gp140-immunized groups (Figure 4B). At 2wp3, the disulfide-
stabilized gp140 generated the highest avidities in comparison to
all other groups. When we followed the antibody avidity after the
end of the 3rd and final immunization, we observed a steady but
comparable decrease across all groups in avidities at 4wp3 and
8wp3 time-points - a trend similar to that seen with antibody
GMT titers (Figure 4A).
When we tested the serum antibodies from the 2wp3 time-point
(peak titers and avidities) for virus neutralization against a panel of
Tier 1 pseudoviruses, we observed that all immunogens were able
to raise immune responses that neutralized only 4–5 out of 13
pseudoviruses. Those pseudoviruses included SHIV-Bal-P4 (sub-
type B), MN.3 (subtype B), SF162.LS (subtype B), MW965.26
(Subtype C) and BX08.16 (subtype B). Among the animals
immunized with gp120 immunogens, the only significant differ-
ence was that the disulfide-stabilized gp120 generated approxi-
mately log-higher antibodies against the homologous (SF162.LS)
virus; the ID50 titers against the rest 4 heterologous viruses were
comparable. Among the animal immunized with gp140 immuno-
gens, the disulfide-stabilized gp140 generated a log-higher
antibodies against all pseudoviruses (SHIV-Bal.P4, MN.3 and
SF162.LS), except MW965.26 where the ID50 titers were
comparable (Figure 5, A-D).
Disulfide-stabilized gp140 generated a more balanced
epitope-specific binding antibody response
From the binding and neutralizing antibody analyses (Figure 4
and 5), we observed that the disulfide-stabilized gp140 generated
higher avidity and slightly improved neutralizing antibody
responses to Tier 1 pseudovirions at the 2wp3 time-point. We
therefore used the sera from the 2wp3 time-point to map the
epitope-specificity of the Env-specific antibodies.
To do so, we generated four SF162 gp120 mutants: gp120DV3
(to map reactivity to V3 loop), gp120DV1V2 (to map reactivity to
Figure 3. Binding affinity analysis of binding of wild-type and disulfide-stabilized SF162 gp120 to sCD4 and mAbs b12 and 17b.
Overlay of binding of varying concentrations of wild-type SF162 gp120 to (A) sCD4, (C) b12 mAb, (E) VRC01 mAb, (G) 17b mAb and (I) 17b mAb
(+sCD4). Overlay of binding of varying concentrations of disulfide-stabilized SF162 gp120 (gp120 L1-SS-L2) to (B) sCD4, (D) b12 mAb, (F) VRC01 mAb,
(H) 17b mAb and (J) 17b mAb (+sCD4). ,250–500 RUs of sCD4 or mAbs, b12, VRC01 or 17b, were immobilized directly onto a CM5 sensor chip via
amine coupling. Varying concentrations of gp120s, either wild-type of disulfide-stabilized, were then injected at 80 ml/min, at 25uC with HBS-EP buffer
as running buffer. The experimental curves were then fitted to a 1:1 Langmuir binding model using BIAevaluation software 3.2 (BIAcore Inc). The red
lines indicate the experimentally derived curves while the black lines indicate curves generated after fitting the experimental data to the 1:1 Langmuir
binding model (BIAevaluation software 3.0). Kon (association rate, in 1/Ms), Koff (dissociation rate, in 1/s) and Kd (dissociation constant, in M) are
indicated for each paired (ligand-analyte) interaction, derived by fitting the experimental data to the 1:1 Langmuir binding model. Chi2 (of #1) refers
to goodness of fit of the statistical model to observed experimental data.
doi:10.1371/journal.pone.0076139.g003
Stabilized Env with Improved CD4i Epitope Exposure
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e76139
V1V2 loop), gp120D368R (to map reactivity to CD4-binding site,
CD4BS) [25–28] and gp120I420R (to map reactivity to CD4-
induced, CD4i, site) [26–29]. These proteins were transiently
expressed in HEK 293 cells and purified using the same protocol
described for the gp120/gp140 immunogens. The gp120 mutants
were evaluated by testing their reactivity (or lack thereof) to CD4-
IgG2 and epitope-directed mAbs (data not shown) [28]. Following
this confirmation, the gp120 mutants were then used in ELISA to
evaluate the 2wp3-sera for reactivity to the four epitopes in
question – V3, V1V2, CD4BS and CD4i-site. We observed that
2wp3-sera from gp120-immunized rabbits elicited ,45–60% of
total binding antibodies directed to the V3-loop and 40–50% of
antibodies to the V1V2-loop, and a much lower fraction to the
CD4BS (15–25%) and the CD4i-site (10–14%) (Figure 6A, filled
red symbols). When the rabbits were immunized with the
disulfide-stabilized gp120 (gp120 L1-SS-L2), we observed differ-
ences in overall percent reactivity of the Env-specific antibodies:
#30–35% anti-V3 antibodies, #15–20% anti-V1V2 antibodies,
$22–27% anti-CD4BS antibodies and ,25–30% anti-CD4i-site
antibodies, with less fractional Ab reactivity to the variable loops
and more to the CD4BS and CD4i sites (Figure 6A, open red
symbols). In rabbits immunized with gp140 protein, we observed
similar trend for epitope-specificity as that of gp120 L1-SS-L2,
except for ,3-fold reduced CD4i-antibodies: #30–35% anti-V3
antibodies, 18–22% anti-V1V2 antibodies, ,15–23% anti-
CD4BS antibodies and 11–12% anti-CD4i-site antibodies
(Figure 6B, blue filled symbols). However, when we used the
disulfide-stabilized gp140 (gp140 L1-SS-L2) as immunogens, all
rabbits in this groups showed similar levels ($25–35%) of
specificity to all four epitopes: ,32–36% anti-V3 antibodies, 25–
34% anti-V1V2 antibodies, ,25–30% anti-CD4BS antibodies
and .30–35% anti-CD4i-site antibodies (Figure 6B, blue open
symbols). Overall, the disulfide-stabilized gp140 (gp140 L1-SS-L2)
generated the most ‘‘balanced’’ epitope-specific response with
similar titers of Abs recognizing each of the specificities evaluated,
in comparison to the wild-type gp120, disulfide-stabilized gp120
and wild-type gp140 immunogens. Unlike the gp120 proteins,
which were homogenously monomeric, the gp140 proteins (both
wild-type and disulfide-stabilized) were less homogenously trimeric
(,85% trimer) [19]; therefore, we cannot rule out the impact of
the gp140-heterogeneity (with ,15% gp140 monomer and dimer),
although potentially low, on epitope-specific responses observed in
the two gp140-immunized groups.
The observation that both the disulfide-stabilized recombinant
proteins, gp120 L1-SS-L2 and gp140 L1-SS-L2, generated
significantly higher levels of binding antibodies directed to the
CD4i-epitope (Figure 6A, B) led us to test if these serum antibodies
would also show relatively higher neutralization properties in
presence of sCD4. To do so, we used 2wp3 sera to neutralize HIV-
2 (7312A/V434M), in the presence or absence of soluble CD4
(sCD4). We observed that, while none of the animals immunized
by gp120 and gp140 elicited antibodies that neutralize sCD4-
induced HIV-2, 3 out of 5 animals (# 7, 8 and 10) immunized
with gp120 L1-SS-L2 and 3 out of 5 animals (# 17, 18 and 19)
immunized with gp140 L1-SS-L2 generated antibodies that
neutralized HIV-2 in the presence of sCD4 (Figure 7). These
Figure 4. Binding analysis of serum antibodies post-immunization. Env binding analysis of serum antibodies from an immunogenicity study
in rabbits using a gp120/gp140 protein-only regimen with Carbopol971P + MF59 [54] as adjuvant. (A) Geometric mean (binding) titers and (B) Avidity
of anti-Env antibodies in sera collected before the onset of immunization (pre-bleed) and at 2wp2, 2wp3, 4wp3 and 8wp3 (wp - weeks post)
immunization time-points.
doi:10.1371/journal.pone.0076139.g004
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Figure 5. Neutralization of pseudoviruses using TZM-bl luciferase-based assay. Neutralization of control (SVA-MLV), SHIV-chimeric (SHIV-
Bal-P4) and HIV-1 pseudoviruses encompassing Tier-1A/B [MN.3 (Subtype B), SF162.LS (Subtype B), MW965.26 (Subtype C), Bx08.16 (Subtype B),
SS1196.1 (Subtype B), 00836.25 (Subtype C), 25710-2.43 (Subtype C), 25711-2.4 (Subtype C), ZM109F.PB4 (Subtype C), TV1.21 (Subtype C), Du156.12
(Subtype C), ZM197M.PB7 (Subtype C)] isolates by 2wp3-sera from rabbits immunized with (A) gp120, (B) gp120 L1-SS-L2, (C) gp140, or (D) gp140 L1-
SS-L2.
doi:10.1371/journal.pone.0076139.g005
Figure 6. Dissection of epitope-specific recognition of antibodies from vaccine sera. Analysis of 2wp3-sera from rabbits for dissecting
specificity of epitopes recognized (expressed as ‘% epitope-directed binding’) by the antibodies elicited when immunized with (A) wild-type gp120
(red solid symbols) or gp120 L1-SS-L2 (red open symbols) or (B) wild-type gp140 (blue solid symbols) or gp140 L1-SS-L2 (blue open symbols). The
percent epitope-directed response is calculated as follows: EC50(mutant)/EC50(wild-type)x100. ns – non-significant (p.0.05); * ,0.05; ** ,0.001.
doi:10.1371/journal.pone.0076139.g006
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data confirm that the disulfide-stabilized immunogens used in this
study elicit significantly higher levels of binding and neutralizing
antibodies directed to the CD4-induced epitope.
Discussion
Despite the promising but modest level of short-lived protection
in the RV144 trial in Thailand, wherein native monomeric gp120
protein antigens were used as boost, identification and production
of a superior recombinant Env-based immunogen for HIV vaccine
development is warranted. Emerging results in the field continue
to suggest that trimeric, functional forms of recombinant Env
might generate more broadly-reactive, neutralizing antibody
responses against HIV [30–34].
Gp120-based protein immunogens have been used in numerous
pre-clinical and clinical studies. In addition to the varying glycan
‘umbrella’ protecting the underlying polypeptide epitope(s) [35]
and hyper-variability in functionally less important regions [36]
that all Env-based immunogens present, gp120, in particular,
displays more non-neutralizing regions and undergoes larger
entropic changes after receptor binding [14,37] than trimeric/
oligomeric Env. The conformational changes of the Env protein
happen at both inter-domain and intra-domain levels. Not only
are the alterations in the inner domain that facilitate co-receptor-
engagements after CD4-binding significantly large [14,37], the
secondary structure rearrangements within the inner domain are
extensive [6]. Moreover, the diversity of gp120 conformations can
act as decoy to evade immune response against key neutralizing
regions. Hence, restricting this inherent conformational flexibility
of Env protein, via rational engineering to optimally display
conserved epitopes, can potentially improve vaccine-induced
immune responses while also allowing for greater stability during
vaccine production. To this end, we focused on the recently
described ‘‘layered’’ architecture in the gp120 inner domain that
displays enhanced structural plasticity amongst the layers,
particularly layer 2 [6]. Although we attempted several modifica-
tions (Table S1), except for stabilizing the two flexible topological
layers (layers 1 and 2), the rest of the mutations failed to generate a
homogenous, disulfide-stabilized gp120 that was conformationally
active (i.e., bound CD4 and underwent CD4-induced conforma-
tional change to allow CD4-directed antibody, 17b, binding). In
addition, the role of layer 3 in structural rearrangements were not
entirely clear, until recently [38]. After rigorous in vitro analysis, we
concluded that insertion of a single disulfide bond [in specific
positions in layer 1 (V65C) and layer 2 (S115C)] was sufficient to
‘lock’ gp120 in its CD4i-state, as evident from kinetic analysis with
the CD4i-site-directed mAb 17b (Figure 3), and generate
conformationally well-folded Env proteins.
We confirmed the formation of the disulfide bond at the
engineered site in gp120 L1-SS-L2 using high-resolution LC/ESI-
FTICR mass spectrometry that allowed detection of the disulfide
bond between 65C and 115C (Figures S2 and S4). During the
analysis, we observed variability in disulfide bonding, particularly
in the C1-V1/V2 region of the protein. This variability is
consistent with recent reports that have directly [39] or indirectly
[40] highlighted that alternative connection of disulfide linkages is
possible in a number of recombinant envelope glycoproteins
generated from CHO and HEK 293T cells. Concomitant
comparative antibody binding analysis using SPR of wild-type
Figure 7. Neutralization of HIV-2 in the presence and absence of sCD4. Individual rabbit sera were tested for neutralizing activity against
HIV-2 (7312A/V434M) in the absence (open bars) or presence (filled bars) of sCD4. The 50% neutralizing titers are shown for the pre-immune (black)
and 2wp3 (red) serum samples. The antigens used for immunization are indicated above each graph (A – gp120, B – gp120 L1-SS-L2, C – gp140, D-
gp140 L1-SS-L2); the numbers on the x-axis indicate the rabbit numbers. The dotted lines indicate the lowest dilution tested, 1:20, that serves as the
background.
doi:10.1371/journal.pone.0076139.g007
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gp120 and disulfide-stabilized gp120 (gp120 L1-SS-L2) also
confirmed the improved exposure of the CD4i-site on the
disulfide-stabilized gp120. Due to technical challenges, we limited
both the analytical analysis for disulfide-bond configuration (via
mass spectrometry) and affinity of mAb binding (via SPR) to
gp120 s.
In the past, we and others have attempted to stabilize the gp120
conformation [16,28,41,42]. While sCD4 or CD4-mimetic com-
pounds stabilized gp120 and exposed the CD4i-site, these
molecules blocked the key conserved receptor-binding epitope
and inhibited the generation of antibody responses against the
CD4BS region [28,41,42]. Dey et al. performed stabilization of
gp120 via combination of cavity filling mutations and inter-
domain (between inner and outer domain) 2-4 disulfide linkages
on a core-gp120 protein with partial or large V3 and/or V1V2
loop deletions [16]. A direct comparison of effects observed in vitro
with disulfide-stabilized, full-length gp120/gp140 described here
to that of Dey et al. [16] is not feasible since the latter contained
only elements of gp120 core. Regardless, the stabilized gp120 core
immunogens generated antibody responses predominantly direct-
ed to the CD4i-site. In this report, although we observed a similar
effect of improved antibody responses to the CD4i-site, due to the
presence of the variable loop regions (V3, V1V2), we also could
observe the modulation of responses to those epitopes, both in
disulfide-stabilized gp120 and gp140. When comparing the
immunogenicity of all four immunogens (gp120, gp120 L1-SS-
L2, gp140, gp140 L1-SS-L2), the reactivity to the CD4BS across
all groups was found to be similar; however, for the disulfide-
stabilized gp120 and gp140, the reactivities to the CD4i-site, were
higher (Figure 6 and 7). Both these in vivo responses are predictive
of the in vitro binding analysis studied for CD4BS and CD4i-site.
However, although V3-reactivity was lower in all groups in
comparison to the group immunized with gp120, the V1V2-
reactivity was very different between wild-type (gp120/gp140) and
disulfide-stabilized (gp120 L1-SS-L2/gp140 L1-SS-L2) Env pro-
teins: higher V1V2-reactivity in wild-type gp120 than its disulfide-
stabilized counterpart, but lower V1V2-reactivity, although non-
significant, in wild-type gp140 than the disulfide-stabilized gp140
(Figure 6). Although it is difficult to elucidate the mechanistic
details of this observed response, we can speculate about the
differences. It is plausible that the inserted disulfide linkage
between layer 1 and 2, which is at the base of the V1V2 loop [6],
restricts the mobility and presentation of V1V2 loop in gp120.
However, how this restriction is then surmounted in gp140 is yet
unclear.
Although the analysis using mutant forms of gp120 s to dissect
epitope-directed binding antibody responses in the vaccine sera is
useful as observed here, it is simplified by analyzing a specific set of
epitopes only. In addition, there is a possibility of overlaps amongst
epitopes in the mutant forms that could contribute to some of the
observed differences amongst the wild-type and the disulfide-
stabilized recombinant Env. Therefore, combination of approach-
es [27,43–46] are often necessary for improved dissection of
antibody-specificity in vaccine or HIV-infected sera.
When analyzing the epitope-directed response generated by all
four Env immunogens, we observed that both the disulfide-
stabilized gp120 and gp140 generated significantly higher levels of
antibodies directed to the CD4i-site (Figures 6 and 7). As opposed
to past CD4/mini-CD4/CD4-mimetic based liganded approaches
[28,41,42] that faced a limitation in generating antibodies directed
to the CD4BS (since the ‘pocket’ was occupied), our ‘single
disulfide-linked’ approach circumvented this limitation and elicited
CD4BS-directed binding antibodies (Figure 6). Since diverse
relationships exist among epitope specificity, neutralization and
effector function [47], generating broader ‘protective’ antibody
responses to the CD4BS, V1V2, C1 and C5, and CD4i epitopes
will contribute to improving efficacy of vaccine(s) against HIV. In
addition, as opposed to the restrictive function of CD4i-directed
antibodies suggested earlier [48], several recent studies have
emphasized the role of antibodies targeting the CD4i epitope
[41,49] and demonstrated the diversity in specificity and
functionality of these antibodies [50].
Overall, although conformational flexibility and structural
plasticity exists between unliganded and liganded forms of HIV-
1 Envs, the extent varies between Envs and the ligand inducing the
conformational changes [5]. Regardless, it is without doubt that
the diversity of conformations displayed by HIV-1 Env allow for
an effective decoy to occlude immune responses against conserved
functional regions. Hence, rational efforts such as this that limit
conformational diversity to enhance immune responses to
conserved epitopes in HIV-1 Env are a step forward towards the
generation of improved vaccine immunogens.
Materials and Methods
Ethics Statement
The study was fully approved (approval no. 09 NVD
044.3.3.09) by the Institutional Animal Care and Use Committee
at Novartis in accordance with the requirements for the humane
care and use of animals as set forth in the Animal Welfare Act, the
Institute for Laboratory Animal Research (ILAR) Guide for the
care and use of laboratory animals, and all applicable local, state
and federal laws and regulations.
Reagents
Monoclonal antibody (mAb) b12 was purchased from Polymun
Scientific (Vienna, Austria). Soluble CD4 (sCD4) was purchased
from Progenics Pharmaceuticals (Tarrytown, NY). The mAb 17b
was provided by Dr. James Robinson. MAb VRC01 was
generated in-house by cloning the sequences of VL and VH
chains (Protein Data Bank [PDB]: 3NGB) [51] into proprietary
Ab-expression vector backbone containing the human CL and CH
chains. The pDNA was then used to transfect HEK 293 cells and
the expressed mAbs-containing supernatants were dia-filtered and
concentrated 106 before purifying using Protein A-affinity
chromatography. The gp120 mutants were generated and
validated, as described previously [27,28].
Generation of recombinant proteins
Recombinant HIV-1 envelope (Env) glycoproteins, gp120 and
gp140, were derived from the subtype B CCR5-tropic strain HIV-
1 SF162 and were produced by transfection of HEK 293 cells. The
layers 1 and 2 disulfide-stabilized gp120 (gp120 L1-SS-L2) and
gp140 (gp140 L1-SS-L2) were also derived from SF162 and
produced in HEK 293 cells. All four glycoproteins were purified
using a three-step purification process involving Galanthus Nivalis-
Agarose (GNA) affinity column, cation-exchange DEAE column
and a final ceramic hydroxyapatite (CHAP) column as described
by Srivastava et al. [52]. Purified glycoproteins were then analyzed
by SDS-PAGE (for level of purity) and immunoblots for specific
reactivity (to anti-SF162 gp140 polyclonal rabbit sera). The
purified glycoproteins were homogeneous (.95% monomer for
gp120 s; .80% trimer for gp140 s) with purity of .98%.
Endotoxin levels in glycoproteins were measured using EndosafeH
cartridges and an EndosafeH-PTSTM spectrophotometer (Charles
River Laboratories International, Inc., Wilmington, MA), and
found to be #0.05 EU/immunization dose.
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Other variants of SF162 gp120 used for epitope-mapping
purposes, such as gp120DV3, gp120DV1V2, gp120 D368R (CD4-
binding site mutant), and gp120 I420R (CD4i site mutant), were
also produced and purified, as described above and previously
[28]. Gp140-miniCD4 complex was generated by covalently
linking a CD4-mimetic miniprotein, miniCD4 (M64U1-SH), to
trimeric gp140 using site-specific disulfide linkages as described
previously [28].
CarbopolH 971P NF (referred to as Carbopol971P in this study)
was purchased from Lubrizol as powder and was then resuspended
in water under sterile conditions to generate a 0.5% homogenous,
low viscosity suspension. The suspension was stored at 4uC until
further use. A 1:1 (v/v) mix of gp140 protein and 0.5% (w/v)
Carbopol971P (pH$3.0) was made for all in vitro evaluations. For
administration in animals, a 1:1 (v/v) mix of gp140 and 0.5% (w/
v) Carbopol971P was first made and the gp140 protein-
Carbopol971P complex incubated for 30 minutes before addition
of an equal volume of MF59, thereby keeping the final
concentration of Carbopol971P suspension administered at
0.125% (w/v). For all Carbopol971P suspensions for in vivo
studies, endotoxin levels were measured using EndosafeH cartridg-
es and an EndosafeH-PTSTM spectrophotometer (Charles River
Laboratories International, Inc., Wilmington, MA).
Analysis of binding affinity using Surface Plasmon
Resonance
To determine the binding affinities of wild-type gp120 and the
disulfide-stabilized gp120, gp120 L1-SS-L2, we used Surface
Plasmon Resonance (SPR)-based BIAcore 3000. ,200 RU of
sCD4 or mAbs b12, VRC01 or 17b were immobilized directly
onto a CM5 sensor chip via amine coupling. Varying concentra-
tions of gp120 s, either wild-type of disulfide-stabilized, were then
injected at 80 ml/min. In the case of +sCD4, the gp120 proteins
were pre-incubated with 2-fold molar excess of sCD4 for 1 hour at
room temperature before injection. The binding analyses were
performed at 25uC with HBS-EP buffer as running buffer. The
experimental curves were then fitted to a 1:1 Langmuir binding
model using BIAevaluation software 3.2 (BIAcore Inc). The
association rate, Kon, dissociation rate, Koff, and the dissociation
constant, Kd, which are derived following the 1:1 fit, are indicated
in Figure 3.
The binding of CCR5 peptide to the gp120 proteins, wild-type
and disulfide stabilized, in the presence or absence of soluble CD4
(sCD4) were performed as described previously [21]. Approxi-
mately 5000 RU of 22-mer tyrosine-sulfated biotinylated N-
terminal CCR5 peptide [21] was immobilized on to a SA chip and
100 nM of gp120/gp120 L1-SS-L2 proteins were injected at
10 ml/min, either alone or upon pre-incubation with sCD4 (2-fold
molar excess, as described above). The binding analyses were
performed at 25uC with HBS-EP buffer as running buffer.
Analysis of disulfide bond using LC/ESI-FTICR MS
To determine disulfide bonding, particularly between the two
engineered cysteines at position 65 and 115, 75 mg of SF162 gp120
L1-SS-L2 protein was alkylated with 4-vinylpyridine, deglycosy-
lated with PNGase F and then digested with trypsin, as described
previously [39]. Following tryptic digestion, samples were analyzed
using a hybrid linear ion trap Fourier Transform-Ion Cyclotron
Resonance (LTQ-FTICR) mass spectrometer coupled with a
Waters NanoACQUITY UltraPerformance Liquid Chromatog-
raphy (UPLC) system. Chromatographic separation was per-
formed using a C18 PepMap 300TM column (150 mm6300 mm
i.d. 5 mM, 300Å; LC Packings, Sunnyvale, CA) that is equilibrated
with 97% mobile phase A (99.9% water with 0.1% formic acid)
and 3% mobile phase B (99.9% acetonitrile with 0.1% formic
acid). Approximately 5 mL of sample was injected into the column
at a flow rate of 5 mL/min using the following gradient: a linear
increase to 40% B in 50 minutes then to 90% B in 10 min. The
column was held at 90% B for 10 min before equilibration. Data
were collected in a data dependent acquisition mode in which the
five most intense ions in a high resolution survey scan in the
FTICR cell were sequentially and dynamically selected for
subsequent collision-induced dissociation (CID) in the LTQ linear
ion trap to ascertain the disulfide connectivity, as described
previously [39].
Rabbit immunizations
Immunization studies were conducted at Josman LLC (Napa,
CA), a research facility that is licensed through the USDA (No. 93-
R-0260) and has a Public Health Service (PHS) Assurance from
the NIH (No. A3404-01). Four groups of New Zealand White
rabbits (5 young adult females per group) were used in the study.
Rabbits were immunized with SF162 gp140 protein adjuvanted
with either MF59 alone, Carbopol971P alone, or with Carbo-
pol971P plus MF59. Three immunizations were administered
intramuscularly, in the gluteus muscle (2 sites per immunization),
at weeks 0, 4, and 12. The protein dosage at each immunization
was 25 mg. Serum samples were prepared from blood collected
prior to the first immunization (pre-bleed) and at various time-
points post each immunization (2wp1, 2wp2, 2wp3, 4wp3 and
8wp3) and analyzed for binding and neutralizing antibody
responses.
For assessment of local reactogenicity associated with injection
of 0.125% (w/v) Carbopol971P, visual observations of skin for
edema and erythema at injection sites were performed pre-dose,
immediately after immunization, and 24 h and 48 h after
immunization. General observations for any obvious clinical signs
were performed immediately after immunization, and 24 and 48 h
post-immunization. Body-weights were also recorded before the
beginning of the study, before each immunization, and 24 and
48 h following each immunization.
The study was fully approved by the Institutional Animal Care
and Use Committee at Novartis (approval no. 09 NVD
044.3.3.09) in accordance with the requirements for the humane
care and use of animals as set forth in the Animal Welfare Act, the
ILAR Guide for the care and Use of Laboratory Animals, and all
applicable local, state and federal laws and regulations.
Envelope-specific antibody ELISA and avidity
measurements
Envelope-specific total antibody titers in sera from rabbits
immunized with Carbopol971P plus MF59-adjuvanted wild-type
gp120, the disulfide-stabilized gp120 (L1-SS-L2 gp120), wild-type
gp140 and the disulfide-stabilized gp140 (L1-SS-L2 gp140) were
quantified by a standard ELISA assay using SF162 gp140 protein,
as previously described [52]. The GMT ELISA titers indicated
here are based on end-point dilution titers. Antibody avidity index
determination was performed using an ammonium thiocyanate
(NH4SCN) displacement ELISA as described elsewhere [52]. All
samples were tested in duplicate and results were expressed as the
NH4SCN concentration required to displace 50% of the bound
serum antibodies.
Mapping of epitope-specific antibody binding
To determine epitope-specific antibodies in 2wp3 sera from
rabbits immunized with Carbopol971P plus MF59-adjuvanted
wild-type gp120, disulfide-stabilized gp120 (L1-SS-L2 gp120),
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wild-type gp140 and the disulfide-stabilized gp140 (L1-SS-L2
gp140), binding of sera to wild-type gp120 (for gp120 based
groups) and wild-type gp140 (for gp140 based groups) were used as
binding references (100%-binding). The mutant (SF162) gp120 s
(gp120DV1V2 – for V1V2-specific reactivity; gp120DV3 – for V3-
specific reactivity; gp120D368R – CD4BS mutant, for CD4BS-
reactivity; and gp120I420R – CD4i-site mutant, for CD4i-site
reactivity) were generated and the ELISA performed using the
D7324 Ab-capture protocol, as previously described [28,53]. The
bound serum antibodies were then washed and detected using a
goat anti-rabbit IgG Fc antibody conjugated to horseradish
peroxidase, and the optical density (OD) determined using a
microplate reader (Molecular Devices) at 450 nm. Percent (%)
epitope-directed binding was calculated by comparing the binding
of sera to wild-type gp120 and mutant gp120 s. Thus, % epitope-
directed binding = (EC50 of binding to gp120 DV3/DV1V2/
D368R/I420R4EC50 of binding to gp120 WT) 6100.
HIV-1 neutralization assays
Virus neutralization titers were measured using a well-
standardized assay employing pseudoviruses and a luciferase
reporter gene assay in TZM-bl cells [Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme, Inc. (Durham, NC)] as described
previously [46,47]. Briefly, 200 TCID50 pseudoviruses/well were
added to diluted serum samples and incubated at 37uC for 1 h.
Following incubation, 10,000 cells/well in DEAE-dextran-con-
taining media were added and incubated for 48 h at 37uC. The
final concentration of DEAE-dextran was 10 mg/ml. After a 48 h
incubation, 100 ml of cells were transferred to 96-well black solid
plates (Costar) for measurements of luminescence using Bright-Glo
substrate solution as described by the supplier (Promega).
Neutralization titers are the dilution at which relative lumines-
cence units (RLU) were reduced by 50% compared to virus
control wells after subtraction of background RLUs. HIV-1 Env
pseudoviruses were prepared by co-transfection of 293T cells with
expression plasmids containing full-length molecularly cloned
gp160 env genes from a panel of HIV-1 isolates combined with an
env-deficient HIV-1 backbone vector (pSG3Denv) using Fu-
GENE-6 HD (Roche Applied Sciences, Indianapolis, IN), as
previously reported [47]. After 48 h, the cell culture supernatants
containing the pseudoviruses were filtered through a 0.45 mm filter
and stored at 280uC until use.
HIV-2 neutralization assays
For the detection of CD4i neutralizing antibodies, a modified
neutralization was used, as previously described [49].
Statistical analyses
Comparisons between multiple groups were carried out using
analysis of variance (1 way ANOVA). A Kruskal-Wallis test was
used to analyze differences between multiple epitope-directed
groups. For all comparisons, a two-sided P,0.05 was considered
statistically significant. All analyses were performed using the
analysis software within the GraphPad Prism package 5.01.
Supporting Information
Figure S1 Primary sequence alignment and schematic
representation of proximity of layer 1 and layer 2 and
insertion of a specific cysteine pair in gp120 inner
domain. (A) Primary sequence alignment of SF162 gp120 and
HxB2 gp120, highlighting the two point mutations in layer 1
(V65C) and layer 2 (S115C) regions of the gp120 sequence. (B)
Ribbon diagram representation showing the targeted position in
layer 1 (magenta, Val65) and layer 2 (green, Ser115), which are
proximal and separated by 3.7Å, for generating the disulfide bond
in the gp120 inner domain. Layer 1 and Layer 2, here on are
referred to as L1 and L2, respectively.
(TIF)
Figure S2 Summary of the disulfide linkages in SF162
gp120 L1-SS-L2 as detected by LC/ESI-FTICR MS. (A)
Major forms of disulfide-linked tryptic peptides, with * highlighting
the formation of a disulfide bond via the engineered cysteine
residues at position 65 and 115. (B) Minor forms of disulfide-linked
tryptic peptides.
(TIF)
Figure S3 Surface Plasmon Resonance (SPR) binding
analysis to show qualitative binding of gp120 proteins,
wild-type and disulfide stabilized, in presence or
absence of soluble CD4 to immobilized CCR5 peptide.
Disulfide-stabilized SF162 gp120 (gp120 L1-SS-L2; orange) bound
to the biotinylated N-terminal CCR5 peptide [21], immobilized
on SA chip, ,5-fold better (at time = 300 s) than the wild-type
gp120 (cyan). When pre-incubated with soluble CD4 (sCD4), both
complexes, gp120+sCD4 (blue) and gp120 L1-SS-L2+sCD4 (red),
bound CCR5 peptide with increased affinity relative to their
unbound gp120 counterparts, as expected (gp120+sCD4 bound
.10-fold better than gp120, gp120 L1-SS-L2+sCD4 bound ,4-
fold better than gp120 L1-SS-L2). In addition, gp120 L1-SS-
L2+sCD4 complex exhibited ,2-fold increased binding to CCR5
as compared to gp120+sCD4 binding to CCR5. The black dotted
curve shows binding of buffer (HBS-EP) alone, as a control, to the
immobilized surface.
(TIF)
Figure S4 Spectra of the new site-specific disulfide in
SF162 gp120 L1-SS-L2. (A) Collision-induced dissociation (CID)
and (B) Electron-transfer dissociation (ETD) spectra of gp120 L1-
SS-L2 to validate that the new disulfide mass is correct and verify
the disulfide connectivity shown in Figure S3. (C) Mapping the
fragment ions from the (CID and ETD) spectra to the gp120
sequence to highlight the formation of the new disulfide and
represent the same in the schematic on right.
(TIF)
Table S1 List of gp120 mutants with their site-specific
(position numbering based on HxB2) cysteine mutations
and their in vitro analysis leading to immunogenicity
testing. List of cysteine mutations in layer 1 (L1), layer 2 (L2) and
layer 3 (L3) of gp120 (to allow disulfide, S-S, bond formations) as
well as a summary of expression, purification and in vitro CD4/
CD4i-directed antibody (17b) binding (via SPR) of those gp120




We thank Drs. Rino Rappuoli, Global Head of Vaccines Research
(Novartis Vaccines & Diagnostics, NVD), and Christian Mandl, Head of
US Vaccines Research (NVD), for their support and encouragement. We
also thank Dr. James Robinson for providing 17b monoclonal antibody;
Mark Wininger, Karen Matsuoka and Frank Situ for their assistance with
cell cultures in generating the recombinant Env proteins.
Author Contributions
Conceived and designed the experiments: AKD, AK, IKS, SWB.
Performed the experiments: AKD, AK, AN, CL, PS, EPG, DFC, YD,
Stabilized Env with Improved CD4i Epitope Exposure
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e76139
KH. Analyzed the data: AKD, AK, EPG, DFC, HD, CL, DM, AC, SWB.
Wrote the paper: AKD, AK, SWB.
References
1. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, et al. (1995)
Expression and characterization of CD4-IgG2, a novel heterotetramer that
neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11: 533–
539.
2. (2010) Global Report: UNAIDS report on the global AIDS epidemic.
3. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009)
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-
infected individuals. Nature 458: 636–640.
4. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1
evades antibody-mediated neutralization through conformational masking of
receptor-binding sites. Nature 420: 678–682.
5. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, et al. (2012) Unliganded
HIV-1 gp120 core structures assume the CD4-bound conformation with
regulation by quaternary interactions and variable loops. Proc Natl Acad
Sci U S A 109: 5663–5668.
6. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, et al. (2010) Structure of
HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture
and basis of conformational mobility. Proc Natl Acad Sci U S A 107: 1166–
1171.
7. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure
of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 393: 648–659.
8. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The
antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705–
711.
9. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005)
Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025–1028.
10. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, et al. (2000) Structures
of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary
isolates. Structure 8: 1329–1339.
11. Kassa A, Madani N, Schon A, Haim H, Finzi A, et al. (2009) Transitions to and
from the CD4-bound conformation are modulated by a single-residue change in
the human immunodeficiency virus type 1 gp120 inner domain. J Virol 83:
8364–8378.
12. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, et al. (2010) Topological
layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-
triggered conformational transitions. Mol Cell 37: 656–667.
13. Kwong PD (2005) Human immunodeficiency virus: refolding the envelope.
Nature 433: 815–816.
14. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Structure of an
unliganded simian immunodeficiency virus gp120 core. Nature 433: 834–841.
15. Kassa A, Finzi A, Pancera M, Courter JR, Smith AB, . (2009) Identification of a
human immunodeficiency virus type 1 envelope glycoprotein variant resistant to
cold inactivation. J Virol 83: 4476–4488.
16. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, et al. (2009) Structure-based
stabilization of HIV-1 gp120 enhances humoral immune responses to the
induced co-receptor binding site. PLoS Pathog 5: e1000445.
17. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition
of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732–737.
18. Chen L, Kwon YD, Zhou T, Wu X, O’Dell S, et al. (2009) Structural basis of
immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:
1123–1127.
19. Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, et al. (2003) Purification,
characterization, and immunogenicity of a soluble trimeric envelope protein
containing a partial deletion of the V2 loop derived from SF162, an R5-tropic
human immunodeficiency virus type 1 isolate. J Virol 77: 11244–11259.
20. Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, et al. (2008) Comparative
evaluation of trimeric envelope glycoproteins derived from subtype C and B
HIV-1 R5 isolates. Virology 372: 273–290.
21. Dey AK, Khati M, Tang M, Wyatt R, Lea SM, et al. (2005) An aptamer that
neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-
CCR5 interaction. J Virol 79: 13806–13810.
22. Yu B, Fonseca DP, O’Rourke SM, Berman PW (2010) Protease cleavage sites in
HIV-1 gp120 recognized by antigen processing enzymes are conserved and
located at receptor binding sites. J Virol 84: 1513–1526.
23. Yu B, Morales JF, O’Rourke SM, Tatsuno GP, Berman PW (2012) Glycoform
and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
PLoS One 7: e43903.
24. Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, et al. (2012) Use of a
polyanionic carbomer, Carbopol971P, in combination with MF59, improves
antibody responses to HIV-1 envelope glycoprotein. Vaccine 30: 2749–2759.
25. Thali M, Olshevsky U, Furman C, Gabuzda D, Li J, et al. (1991) Effects of
changes in gp120-CD4 binding affinity on human immunodeficiency virus type
1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol 65: 5007–
5012.
26. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, et al. (1991)
Characterization of a discontinuous human immunodeficiency virus type 1
gp120 epitope recognized by a broadly reactive neutralizing human monoclonal
antibody. J Virol 65: 6188–6193.
27. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, et al. (2009) Analysis of
neutralization specificities in polyclonal sera derived from human immunode-
ficiency virus type 1-infected individuals. J Virol 83: 1045–1059.
28. Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, et al. (2012) Elicitation of
neutralizing antibodies directed against CD4-induced epitope(s) using a CD4
mimetic cross-linked to a HIV-1 envelope glycoprotein. PLoS One 7: e30233.
29. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE (2002)
Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope
glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS
Res Hum Retroviruses 18: 1207–1217.
30. Kovacs JM, Nkolola JP, Penga H, Cheung A, Perry J, et al. (2012) HIV-1
envelope trimer elicits more potent neutralizing antibody responses than
monomeric gp120. Proc Natl Acad Sci USA(in press).
31. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, et al. (2007) A
comparative immunogenicity study in rabbits of disulfide-stabilized, proteolyt-
ically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140,
trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329–
340.
32. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, et al. (2007) Extensively
cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immuniza-
tion. Proc Natl Acad Sci U S A 104: 10193–10198.
33. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, et al. (2007) Characterization of
human immunodeficiency virus type 1 monomeric and trimeric gp120
glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and
immunogenicity. J Virol 81: 5579–5593.
34. Forsell MN, Schief WR, Wyatt RT (2009) Immunogenicity of HIV-1 envelope
glycoprotein oligomers. Curr Opin HIV AIDS 4: 380–387.
35. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody
neutralization and escape by HIV-1. Nature 422: 307–312.
36. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens,
antigens, and immunogens. Science 280: 1884–1888.
37. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, et al. (2000)
Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A
97: 9026–9031.
38. Desormeaux A, Coutu M, Medjahed H, Pacheco B, Herschhorn A, et al. (2013)
The Highly Conserved Layer-3 Component of the HIV-1 gp120 Inner Domain
Is Critical for CD4-Required Conformational Transitions. J Virol 87: 2549–
2562.
39. Go EP, Zhang Y, Menon S, Desaire H (2011) Analysis of the disulfide bond
arrangement of the HIV-1 envelope protein CON-S gp140 DeltaCFI shows
variability in the V1 and V2 regions. J Proteome Res 10: 578–591.
40. Jobes DV, Daoust M, Nguyen V, Padua A, Michele S, et al. (2006) High
incidence of unusual cysteine variants in gp120 envelope proteins from early
HIV type 1 infections from a Phase 3 vaccine efficacy trial. AIDS Res Hum
Retroviruses 22: 1014–1021.
41. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, et al. (2007) Antibodies to
CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in
macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 104:
17477–17482.
42. Martin G, Burke B, Thai R, Dey AK, Combes O, et al. (2011) Stabilization of
HIV-1 envelope in the CD4-bound conformation through specific crosslinking
of a CD4 mimetic. J Biol Chem.
43. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, et al. (2008) Improved
induction of antibodies against key neutralizing epitopes by human immuno-
deficiency virus type 1 gp120 DNA prime-protein boost vaccination compared
to gp120 protein-only vaccination. J Virol 82: 7369–7378.
44. Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, et al. (2005)
Characterizing anti-HIV monoclonal antibodies and immune sera by defining
the mechanism of neutralization. Hum Antibodies 14: 101–113.
45. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. (2008)
Profiling the specificity of neutralizing antibodies in a large panel of plasmas
from patients chronically infected with human immunodeficiency virus type 1
subtypes B and C. J Virol 82: 11651–11668.
46. Grundner C, Li Y, Louder M, Mascola J, Yang X, et al. (2005) Analysis of the
neutralizing antibody response elicited in rabbits by repeated inoculation with
trimeric HIV-1 envelope glycoproteins. Virology 331: 33–46.
47. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, et al. (2012)
Diverse specificity and Q:1 effector function among human antibodies to HIV-1
envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad
Sci U S A(in press).
48. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of
antibody molecules to the conserved coreceptor binding site on glycoprotein
gp120 is sterically restricted on primary human immunodeficiency virus type 1.
J Virol 77: 10557–10565.
49. Huang CC, Stricher F, Martin L, Decker JM, Majeed S, et al. (2005) Scorpion-
toxin mimics of CD4 in complex with human immunodeficiency virus gp120
Stabilized Env with Improved CD4i Epitope Exposure
PLOS ONE | www.plosone.org 12 October 2013 | Volume 8 | Issue 10 | e76139
crystal structures, molecular mimicry, and neutralization breadth. Structure 13:
755–768.
50. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, et al. (2013)
Diverse specificity and effector function among human antibodies to HIV-1
envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad
Sci U S A 110: E69–78.
51. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for
broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:
811–817.
52. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, et al. (2002) Purification
and characterization of oligomeric envelope glycoprotein from a primary R5
subtype B human immunodeficiency virus. J Virol 76: 2835–2847.
53. Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, et al. (2008) N-terminal
substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope
glycoproteins on the virus. Virology 372: 187–200.
54. Dey AK, Burke B, Sun Y, Hartog H, Heeney JL, et al. (2012) Use of a
polyanionic carbomer, Carbopol971P, in combination with MF59, improves
antibody responses to HIV-1 envelope glycoprotein Manuscript under review.
Stabilized Env with Improved CD4i Epitope Exposure
PLOS ONE | www.plosone.org 13 October 2013 | Volume 8 | Issue 10 | e76139
